Watch our roundtable discussion featuring experts from TrakCel, Ori Biotech, ScaleReady, and RoslinCT
Rob Coker | | Video
sponsored by IDBS
The gears driving Industry 4.0 continue to catalyze many aspects of production in all industries. Known traditionally for lagging somewhat in this uptake, we gathered four experts to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing.
Jason Foster, CEO of tech provider Ori Biotech, has a vision to expand production at a scale that will meet demand for the first time. He recognises that automation and digitization will be crucial for the future of CGT manufacturing, and is working towards bringing these Industry 4.0 solutions to advanced therapies.
TrakCel’s VP Scientific Affairs, Matthew Lakelin, understands that the number of partners needed for the development and manufacture of a cell therapy can create a logistical nightmare, and paperwork can seem to take over. TrakCel has developed digital cellular orchestration solutions for clinical trials and commercial therapies, digitizing the process and simplifying supply chain visibility.
Josh Ludwig, Global Director of ScaleReady, sees the potential automation could have for cell therapy to scale up. But with progress rarely linear, the ability to scale down to adjust processes is also invaluable. Using the company’s suite of tools, he’s helped partners develop never-before-seen approaches to moving backwards and forwards easily, building an efficient process that gets advanced therapies to patients faster.
Barbara Ressler, VP, Manufacturing Process Sciences, is responsible for managing the Analytical Development, Process Development, and Manufacturing Sciences & Technology (MS&T) teams. The mission of these teams is to create robust, GMP-compliant processes and assays for RoslinCT’s partners, and to facilitate transfer to Manufacturing and QC.
Learn how IDBS PIMS platform makes BioPharma manufacturing process data accessible, transferable and meaningful.